Investment
Innovation
market access
Singapore-based venture builder community focused on bringing capital and medical innovation to the Asia-Pacific region, with social impact goals in mind.
Thailand
Vietnam
Taiwan
South Korea
Philippines
Singapore
Indonesia
USA
Partnering with
about Heal veture lab
Heal Venture Lab is a venture builder community focused on bringing capital and outcome-driven medical innovations to Asia Pacific to improve on healthcare access and affordability. The company is creating a regional accelerator with focus on biomed product and service innovations on critical unmet epidemiology while creating a hub and spoke network for Asia with Singapore as the central hub.
Engagement Model
Stakeholder Economy
the due diligence on both sides
The Three Pillars of the Barbel Model
THE ENGINE
High-risk early-stage platforms and “Drug Factories.”
→ Option Value & Convexity
→ 10x – 30x ROI Target
→ Power Law Fund Returner
THE SWEET SPOT
Clinical value inflections (Phase 1b to Phase 2 PoC).
→ De-risking Inflection
→ 3x – 7x ROI Target
→ Primary M&A Exit Zone
THE FLOOR
Late-stage Medtech, Diagnostics, or Digital Health.
→ Capital Preservation
→ ~2x ROI Target
→ DPI & Velocity Focus
“Strategic Objective: Protect the J-Curve via the Floor while capturing exponential Alpha via the Engine.”
Investment Process
Deal Origination
Initial Assessment (Pre-NDA)
Singapore-based venture builder community focused on bringing capital and medical innovation to the Asia-Pacific region, with social impact goals in mind.
Assessment (Post-NDA)
Screening based on company information, TPP, DD questionnaire, and advisor feedback
Due Diligence
Overall investment plan and strategy
Investment Committee
Overall investment plan and strategy
Deal Structuring
To confirm all relevant information
Value Creation
Exit Strategy
Deal Origination
Initial Assessment (Pre-NDA)
Singapore-based venture builder community focused on bringing capital and medical innovation to the Asia-Pacific region, with social impact goals in mind.
Assessment (Post-NDA)
Screening based on company information, TPP, DD questionnaire, and advisor feedback
Due Diligence
Overall investment plan and strategy
Investment Committee
Overall investment plan and strategy
Deal Structuring
To confirm all relevant information
Value Creation
Exit Strategy
Market Access
Regional Network Expansion for Market Access
Current Market
Upcoming Market
See all events per market
- Singapore (15)
- South Korea (12)
- Vietnam (1)
- Thailand (5)
- Indonesia (9)
- Philippines (8)
- USA (2)
News and Updates
FOCUS AREAS
Bridging Innovation, Capital, and Market Access in Asia
Innovation
Therapeutic areas and unmet medical needs
Affordability and accessibility
Outcome-driven, scalable, and sustainable ventures
capital
Sector & Stage
Advanced medtech, biotech, and digital health
Early to growth stage
(pre-A to Series B)
market access
Core Capabilities
Regulatory submission and reimbursement strategy
Clinical development and trial support
Manufacturing, distribution, and commercial partnerships
Startups and Investors
We bridge medical innovation with capital and market access by turning unmet needs into investable opportunities.
CATEGORY
Startups
Investors
Access
Capital, partners, expertise regulatory
Proprietary deal flow
Derisking
Reimbursement, commercialization
Technical market and management due diligence
Acceleration
Capital, partners, expertise regulatory
Early access to high-growth med tech opportunities
Sustainability
Scalable outcome-based models
Long-term impact-aligned returns
Startups and Investors
Discovery & Early Planning
Market validation, unmet need mapping, regulatory planning
Clinical & Reimbursement
Study design, CRO/CRO access, reimbursement strategy
Growth and Exit
Fundraising, investor syndication, strategic exits
Market Access & Distribution support
Study design, CRO/CRO access, reimbursement strategy
Scale-up & Manufacturing Localization
Partner introductions, manufacturing localization
